
Sign up to save your podcasts
Or
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
4.8
3939 ratings
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.
Key topics discussed include:
Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.
Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at [email protected]
323 Listeners
41 Listeners
111 Listeners
506 Listeners
60 Listeners
1,117 Listeners
182 Listeners
45 Listeners
23 Listeners
362 Listeners
28 Listeners
277 Listeners
60 Listeners
181 Listeners
48 Listeners